Seelos Therapeutics SEEL Stock News

Seelos Therapeutics Inc (NASDAQ: SEEL) had a great day in the market on Thursday. By the closing bell, the stock was trading at $3.22 per share after a gain of $0.16 per share or 5.23%. Nonetheless, these gains may just be the tip of the iceberg.

A recent interview sparked interest in the efforts that SEEL is making in the Sanfilippo Syndrome space.

SEEL CEO Appears In An Interview About Sanfilippo Syndrome

As you can see in the video above, Raj Mehra, PhD, CEO at Seelos Therapeutics recently appeared in an interview for CheckRare.com. In the interview, the CEO of the company discussed Sanfilippo Syndrome, also known as MPS III.

MPS III is a progressive disorder that primarily affects the brain and spinal cord. While those who have the condition do not display features of the condition at birth, they do begin to show signs of the disorder in early childhood.

MPS III is known to lead to delayed speech and behavior problems. Children with the condition may also become restless, destructive, anxious, or agressive. In later stages, patients start to develop seizures. Unfortunately, the disease tends to lead to a shorter lifespan, with victims living into adolescence or early adulthood.

SEEL And MPS III Or Sanfilippo Syndrome

Seelos Therapeutics is no stranger to Sanfilippo Syndrome. In fact, one of the company’s core assets, SLS-005, was developed as an option to treat the condition. Currently, the company is in the midst of Phase 2 clinical trials surrounding SLS-005 as a potential treatment for MPS III.

With that said, the fact that the CEO at SEEL appeared in an interview, discussing Sanfilippo Syndrome, is leading to quite a bit of speculation. Honestly, the speculation makes sense.

At the end of the day, CEOs make heavily calculated moves. That is especially the case when it coms to the media. The idea that the CEO appeared in the interview as a prelude to something bigger is not far fetched at all. So, what may be on the horizons?

My Prediction Is Two-Fold

In my opinion, there are two potential releases that we could see relatively soon, following the interview with CheckRare.com. Here’s what I think may happen:

  • The most likely coming release has to do with the Phase 2 clinical trial of SLS-005. Considering the timing, and the fact that the CEO at SEEL discussed the targeted indication in the interview, it wouldn’t be a surprise to see a data release or other update with regard to the clinical trial come down the line.
  • Another potential release that may come down the line surrounds the company’s continued innovation. It’s possible that the company will announce a new clinical development program, targeting the MPS III indication.

Nonetheless, it’s important to keep in mind that both of these potential outcomes are rooted in speculation. I have no inside knowledge, nor have I seen any indication that one of the two potential outcomes will actually take place. My view on these potential outcomes is based solely on the interview between CheckRare.com and the CEO at SEEL, in combination with the company’s work in Sanfilippo Syndrome.

Final Thoughts

While this article primarily focused on Sellos Therapeutics’ work in the MPS III indication, it’s also worth mentioning that the company has a robust pipeline, targeting a wide array of indications. Although the vast majority of the company’s pipeline is in early-to-mid-stages, data surrounding these assets has proven to be positive.

This, combined with my view that SEEL will likely issue news relatively soon makes this a compelling growth opportunity in the making in my view.

What Do You Think?

Where do you think SEEL is headed moving forward? Join the discussion in the comments below!

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.